Introduction A. Sajnic (Zagreb, Croatia), J. Padilha (Porto, Portugal)
| |
Introduction L. Uller (Lund, Sweden), F. Salgado Castro (Santiago De Compostela, Spain)
| |
Introduction T. Troosters (Leuven, Belgium), A. Holland (Fitzroy North (VIC), Australia)
| |
Introduction A. Mathioudakis (Stockport, United Kingdom), M. Lommatzsch (Rostock, Germany)
| |
Chronic NIV in patients with COPD: what is the best way to go? C. Cantero (Paris, France)
| |
Interactive cases by participants S. Loukides (Athens, Greece), M. Barrecheguren Fernandez (Barcelona, Spain), D. Stolz (Basel, Switzerland), K. Kostikas (Ioannina, Greece), A. Papi (Cona, Ferrara, Italy), M. Han (Ann Arbor, United States)
| |
COPD exacerbations: Importance and controversies A. Papi (Cona, Ferrara, Italy)
| |
Making sense of phenotypes and endotypes in COPD D. Stolz (Basel, Switzerland)
| |
Assessing and monitoring COPD M. Han (Ann Arbor, United States)
| |
Latest updates in the guidelines for COPD: diagnosis and management K. Kostikas (Ioannina, Greece)
| |
Discussion and Q&A
| |
How do we eliminate COPD? M. Dransfield (Birmingham, United States)
| |
Pharmacological and nonpharmacological unmet needs in COPD D. Sin (Vancouver (BC), Canada)
| |
Revisiting the diagnosis and classification of COPD D. Stolz (Basel, Switzerland)
| |
Why is COPD a pandemic? What matters to patients? M. Han (Ann Arbor, United States)
| |
Lockdown impact in patients with severe and very severe COPD S. Miranda Valladares (Santa Cruz de Tenerife, Spain), M. Entrambasaguas Martin (Malaga, Spain), B. Gonzalez Sanchez (Malaga, Spain), M. Perez Redondo (Malaga, Spain), F. Bernal Prados (Malaga, Spain), M. Prunera Pardell (Malaga, Spain), A. Domenech Del Rio (Malaga, Spain)
| |
Pulmonary telerehabilitation in the COVID era - pilot program S. Alves Vaz (Vila Real, Portugal), A. Loureiro (Vila Real, Portugal), R. Rodrigues (Vila Real, Portugal), M. Padilha (Porto, Portugal)
| |
Pulmonary rehabilitation maintenance programmes: What makes the difference? L. Silva (Porto, Portugal), T. Maricoto (Aveiro, Portugal), P. Costa (Braga, Portugal), J. Berger (Bern, Switzerland), M. Padilha (Porto, Portugal)
| |
Pain perception in COPD patients across the COVID-19 pandemic M. Granados Santiago (Granada, Spain), J. González Dueñas (Granados, Spain), A. Calvache Mateo (Granados, Spain), Á. Benítez Feliponi (Granados, Spain), A. Heredia Ciuró (Granados, Spain), M. Valenza (Granados, Spain)
| |
Patients’ experience of automated oxygen administration during hospitalization with acute exacerbation in COPD - a qualitative study. C. Bech (Hvidovre, Denmark), I. Poulsen (Hvidovre, Denmark), V. Nørholm (Hvidovre, Denmark), D. Bove (Hillerød, Denmark)
| |
The impact on number of hospitalizations and lenght of hospital stay for patients with advanced COPD affiliated with a cross-sectorial lung team. B. Refsgaard Iversen (Aarhus , Denmark), L. Rodkjaer (Aarhus , Denmark), V. Bregnballe (Aarhus , Denmark), A. Løkke (Vejle, Denmark)
| |
Impact on the quality of life of patients with COPD after three non-pharmacological interventions. S. Miranda Valladares (Santa Cruz de Tenerife, Spain), B. Gonzalez Sanchez (Malaga, Spain), M. Entrambasaguas Martin (Malaga, Spain), F. Bernal Prados (Malaga, Spain), M. Perez Redondo (Malaga, Spain), M. Prunera Pardell (Malaga, Spain), A. Domenech Del Rio (Malaga, Spain)
| |
Comparing results of the Asthma Control Test and Severe Asthma Quality of life Questionnaire in patients with severe asthma on biologics M. Rezelj (Golnik, Slovenia), J. Tršan (Golnik, Slovenia), I. Pocvavšek (Golnik, Slovenia), T. Mocnik (Golnik, Slovenia), A. Simonic (Golnik, Slovenia), T. Morgan (Golnik, Slovenia), P. Kopac (Golnik, Slovenia), S. Škrgat (Ljubljana, Slovenia)
| |
Embolie pulmonaire et exacerbation de BPCO / Pulmonary embolism and exacerbation of COPD F. Couturaud (Brest, France)
| |
Annual and post-exacerbation follow-up of COPD patients in clinical practice – a large population-based study in Sweden H. Sandelowsky (Solna, Sweden), C. Janson (Uppsala, Sweden), F. Wiklund (Uppsala, Sweden), G. Telg (Sodertalje, Sweden), S. De Fine Licht (Sodertalje, Sweden), B. Ställberg (Uppsala, Sweden)
| |
Effectiveness of a long-term home-based exercise training in COPD patients: The HOMEX-2 RCT A. Frei (Zürich, Switzerland), T. Radtke (Zürich, Switzerland), K. Dalla Lana (Zürich, Switzerland), R. Kunz (Zürich, Switzerland), T. Cerini (Zürich, Switzerland), M. Puhan (Zürich, Switzerland)
| |
Molecular signatures of SARS-CoV2 in vitro infection of bronchial epithelium from CF, COPD and healthy subjects L. Guillot (Paris, France), J. Oliva (Lyon, France), M. Ruffin (Paris, France), C. Calmel (Paris, France), H. Corvol (Paris, France), O. Terrier (Lyon, France)
| |
The ROSE criteria for coexistent COPD-bronchiectasis: association with future exacerbations and death W. Dolliver (Boston, MA, United States), W. Wang (Boston, MA, United States), J. Orejas (Boston, MA, United States), D. Maselli (San Antonio, TX, United States), A. Yen (San Diego, CA, United States), K. Young (Aurora, CO, United States), G. Kinney (Aurora, CO, United States), M. Cho (Boston, MA, United States), R. San José Estépar, (Boston, MA, United States), A. Diaz (Boston, MA, United States)
| |
Factors associated with specific causes of death in a primary care COPD population in England H. Whittaker (London, United Kingdom), K. Rothnie (London, United Kingdom), J. Quint (London, United Kingdom)
| |
COVID-19 real-world data (RWD) insights regarding exacerbations and serum Eosinophil levels in Asthma and Chronic Obstructive Pulmonary Disease (COPD). M. Cushion (Biggleswade, United Kingdom)
| |
Frequency and severity of respiratory infections prior to COPD diagnosis and risk of subsequent post-diagnosis COPD exacerbations and mortality: a UK routine health care data study H. Whittaker (London, United Kingdom), C. Nordon (Cambridge, United Kingdom), A. Rubino (Cambridge, United Kingdom), T. Morris (Luton, United Kingdom), Y. Xu (Luton, United Kingdom), E. De Nigris (Cambridge, United Kingdom), H. Müllerová (Cambridge, United Kingdom), J. Quint (London, United Kingdom)
| |
Plasma IgE and risk of exacerbation and mortality in COPD in the general population Y. Çolak (Copenhagen, Denmark), T. S. Ingebrigtsen (Copenhagen, Denmark), B. G. Nordestgaard (Copenhagen, Denmark), J. L. Marott (Copenhagen, Denmark), P. Lange (Copenhagen, Denmark), J. Vestbo (Manchester, United Kingdom), S. Afzal (Manchester, United Kingdom)
| |
Nurses specialized through higher education in asthma, allergy and COPD. Experiences from a Swedish perspective - A winning concept for the clinic C. Stridsman (Umeå, Sweden), A. Zakrisson (Örebro, Sweden), T. Sterner (Malmö, Sweden)
| |
A palliative approach to COPD M. Johnson (Hull (North Humberside), United Kingdom)
| |
COPD and sexual health A. Rodrigues Silva (Vila do Conde, Portugal)
| |
COPD and mental health I. Tsiligianni (Heraklion (Crete), Greece)
| |
Discussion and Q&A
| |
Diagnostic strategies for venous thromboembolism Y. Freund (Paris, France)
| |
Screening for COPD J. Hurst (London, United Kingdom)
| |
Non-invasive respiratory support strategies for acute hypoxemia in COVID-19 G. Perkins (Birmingham (West Midlands), United Kingdom)
| |
Impact of ActiGraph® cutoffs on time spent in moderate to vigorous physical activities in COPD. P. Sobral Rebelo (Aveiro, Portugal), J. Antão (Aveiro, Portugal), S. Almeida (Aveiro, Portugal), D. Brooks (Hamilton, Canada), A. Marques (Aveiro, Portugal)
| |
Reference equations for quadriceps function in COPD: a multicenter study S. Tanguay (Québec (QC), Canada), D. Saey (Québec (QC), Canada), A. Nyberg (Ulmea, Sweden), S. Marklund (Ulmea, Sweden), E. Frykholm (Ulmea, Sweden), J. De Brandt (Hasselt, Belgium), C. Burtin (Hasselt, Belgium), F. Maltais (Québec (QC), Canada)
| |
Differences in pulmonary and extra-pulmonary traits between women and men with COPD S. Souto-Miranda (Horn, Netherlands), A. Van ‘t Hul (Nijmegen, Netherlands), A. Vaes (Horn, Netherlands), J. Antons (Nijmegen, Netherlands), R. Djamin (Breda, Netherlands), D. Janssen (Horn, Netherlands), F. Franssen (Horn, Netherlands), A. Marques (Aveiro, Portugal), M. Spruit (Horn, Netherlands)
| |
COPD Origins: Understanding Extracellular Matrix (ECM) Remodelling using bio-imaging techniques C. Kong (Southampton (Hampshire), United Kingdom), T. Havelock (Southampton (Hampshire), United Kingdom), M. Bennett (Southampton (Hampshire), United Kingdom), J. Sand (HERLEV, Denmark), S. Rønnow (HERLEV, Denmark), C. Spalluto (Southampton, United Kingdom), S. Karl (Southampton, United Kingdom), K. Ostridge (Gothenburg, Sweden), H. Burke (Southampton (Hampshire), United Kingdom), A. Freeman (Southampton (Hampshire), United Kingdom), A. Fazleen (Southampton (Hampshire), United Kingdom), T. Wilkinson (Southampton (Hampshire), United Kingdom)
| |
How to assess and improve inhaler adherence? F. Lavorini (Firenze (FI), Italy)
| |
How to monitor and improve inhaler technique? H. Chrystyn (Bingley (West Yorkshire), United Kingdom)
| |
How to choose and use an inhaler device? O. Usmani (London, United Kingdom)
| |
Hyperpolarised gas MRI to guide patient management in severe asthma and COPD S. Svenningsen (Hamilton, Canada)
| |
Short-term effects of weather and air pollution on physical activity in COPD patients A. Josa (Barcelona, Spain), A. Arbillaga-Etxarri (Donostia, Spain), E. Balcells (Barcelona, Spain), N. Celorrio (Barcelona, Spain), A. Marin (Barcelona, Spain), M. Monteagudo (Barcelona, Spain), D. A. Rodríguez (Barcelona, Spain), R. Rodríguez-Roisin (Barcelona, Spain), M. Bosch De Basea (Barcelona, Spain), M. Foraster (Barcelona, Spain), P. Simonet (Barcelona, Spain), P. Torán-Monserrat (Mataró, Spain), P. Vall-Casas (Barcelona, Spain), J. Garcia-Aymerich (Barcelona, Spain)
| |
Oxidised IL-33 signals via RAGE/EGFR to drive a COPD-associated phenotype S. Strickson (Cambridge, United Kingdom), K. Houslay (Cambridge, United Kingdom), V. Negri (Cambridge, United Kingdom), Y. Ohne (Gaithersburg, United States), T. Ottosson (Gothenburg, Sweden), R. Dodd (Cambridge, United Kingdom), C. Chaillan Huntington (Cambridge, United Kingdom), J. Li (Cambridge, United Kingdom), H. Killick (Cambridge, United Kingdom), D. Rees (Cambridge, United Kingdom), S. Koch (Cambridge, United Kingdom), G. Sims (Gaithersburg, United States), I. Scott (Cambridge, United Kingdom), X. Romero Ros (Cambridge, United Kingdom), E. Cohen (Cambridge, United Kingdom)
| |